Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

909.17 +1.85 (+0.20%)
Streaming Delayed Price Updated: 12:52 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
Stock Split Watch: Is Regeneron Pharmaceuticals Next?
If the biotech does split its stock, it will be a first for the company. 
Via The Motley Fool
Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Examining the Quality Attributes of NASDAQ:REGN.
Why the quality investor may take a look at REGENERON PHARMACEUTICALS (NASDAQ:REGN). 
Via Chartmill
Analyst Expectations for Regeneron Pharmaceuticals's Future
Via Benzinga
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in 9/19 Morning Trading
Via Investor Brand Network
Three Of Our Top Picks For Your Healthcare Portfolio
Amidst macro uncertainty, healthcare stocks should outperform. 
Via Talk Markets
Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Are Gene Therapy Stocks The Market's Next Big Winners?
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today
Via Benzinga
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
Via Benzinga
Argenx's 28% Surge & Promising Product Propel Investor Confidence
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target. 
Via MarketBeat
This Recent FDA Approval Could Give Regeneron's Top Line a Big Boost
A higher-dose version of Eylea will help the company fight off competition and increase revenue. 
Via The Motley Fool
Exposures Product Safety
3 Stocks to Buy to Ride Europe’s Coming Market Surge
With Europe’s markets looking to perform better in the second half of 2023, here are three European stocks to buy to ride the wave. 
Via InvestorPlace
AI Integration In Biotech & Pharma: Companies Positioned To Benefit
The convergence of artificial intelligence (AI) with the biotech and pharmaceutical sectors is ushering in a new era of innovation. AI is catalyzing transformations from drug discovery to patient care.... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Check Out What Whales Are Doing With REGN
Via Benzinga
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in 9/8 Morning Trading
Via Investor Brand Network
If You Invested $100 In This Stock 20 Years Ago, You Would Have $4,000 Today
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2023
Via Benzinga
New to Investing? Here's How You Can Get Started With $500.
You don't have to invest a lot to start building a winning portfolio. 
Via The Motley Fool
3 Unstoppable Growth Stocks to Buy Right Now
These healthcare stocks show no signs of slowing down. 
Via The Motley Fool
Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity
Via Benzinga
Regeneron Provides Update on Planned Chief Financial Officer Transition
Robert E. Landry to retire effective February 2024; Christopher Fenimore, long-standing Senior Vice President, Head of Accounting and Controller, to assume CFO role 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Announces Updates to Board of Directors
Kathryn Guarini, Ph.D., and David P. Schenkein, M.D., join Regeneron’s Board of Directors 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
2 Top Biotech Stocks to Buy in September
There is rarely a bad time to buy stocks with massive upside potential. 
Via The Motley Fool
Could This Biosimilar Drug Be Novartis' Next Blockbuster?
Novartis expects to submit regulatory applications for its biosimilar soon. 
Via The Motley Fool
Is REGENERON PHARMACEUTICALS (NASDAQ:REGN) suited for quality investing?
This article explores why quality investors may have a look at REGENERON PHARMACEUTICALS (NASDAQ:REGN) 
Via Chartmill
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Acer Therapeutics Inc. (Nasdaq - ACER), Sovos Brands, Inc. (Nasdaq - SOVO), Computer Task Group, Incorporated (Nasdaq - CTG), Decibel Therapeutics, Inc. (Nasdaq -
From Brodsky & Smith LLC
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.